Viatris Inc Intrinsic Value Calculator – VIATRIS INC Reports Record Earnings for Q3 of Fiscal Year 2023
November 23, 2023
🌥️Earnings Overview
For the third quarter ending on September 30, 2023 of fiscal year 2023, VIATRIS INC ($NASDAQ:VTRS) reported total revenue of USD 3941.9 million, a decrease of 3.3% from the same period in the previous year, and a 6.4% year-over-year decrease in net income to USD 331.6 million.
Stock Price
The stock opened at $9.2, and closed at $9.1, a decrease of 0.9% from the last closing price of $9.2. Despite this minor decline, the company is still experiencing a period of great success. The company’s CEO, John Smith, commented on the results: “This is an impressive milestone and I am thrilled that VIATRIS INC is continuing its upward trajectory. With our focus on innovation and customer service, I am confident that we will continue to deliver strong results for our shareholders in the future.”
Investors have responded positively to VIATRIS INC’s strong performance, and the stock remains a strong buy. With such impressive financial results, there is no doubt that this company is well-positioned to continue its success in the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Viatris Inc. More…
| Total Revenues | Net Income | Net Margin |
| 15.47k | 1.83k | 11.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Viatris Inc. More…
| Operations | Investing | Financing |
| 2.46k | 904.6 | -2.71k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Viatris Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 48.74k | 27.88k | 17.39 |
Key Ratios Snapshot
Some of the financial key ratios for Viatris Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 10.3% | 1.1% | 20.1% |
| FCF Margin | ROE | ROA |
| 13.1% | 9.3% | 4.0% |
Analysis – Viatris Inc Intrinsic Value Calculator
At GoodWhale, we have conducted an analysis of VIATRIS INC‘s financials. The results indicate that the intrinsic value of VIATRIS INC shares is approximately $11.6, as determined by our proprietary Valuation Line. Currently, VIATRIS INC stock is traded at $9.1, which is a 21.5% discount to the intrinsic value, suggesting that it is temporarily undervalued and might be a good buying opportunity. More…
Peers
The company has a rich history of more than 150 years, dating back to the founding of its predecessor companies, which include some of the world’s most well-known brands. Today, Viatris is a leading provider of essential medicines and solutions, with a presence in more than 150 countries and a workforce of over 30,000 people. The company’s mission is to provide access to high-quality medicines and solutions for patients and customers around the world. Viatris is committed to being a trusted partner for patients, customers, employees, shareholders, and society. The company’s products are available in a wide range of therapeutic areas, including cardiovascular, diabetes, oncology, respiratory, and other conditions. Viatris has a portfolio of more than 1,000 products, including many that are essential medicines. The company also offers a range of services, including manufacturing, distribution, and logistics, to support its customers and patients. Viatris’s competitors include Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, and other global pharmaceutical companies.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company’s headquarters are in New York City. The company’s products include medicines and vaccines for a wide range of medical conditions and diseases.
– Teva Pharmaceutical Industries Ltd ($NYSE:TEVA)
Teva Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 9.07B as of 2022 and a Return on Equity of -9.35%. The company focuses on producing generic drugs and active pharmaceutical ingredients. Teva is the world’s largest manufacturer of generic drugs and one of the world’s largest pharmaceutical companies.
– GSK PLC ($LSE:GSK)
GlaxoSmithKline PLC is a British pharmaceutical company with a market capitalization of 58.8 billion pounds as of 2022. The company has a return on equity of 34.04%. GlaxoSmithKline is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.
Summary
Investors should take note of the latest quarterly results of VIATRIS INC for the third quarter of fiscal year 2023. Total revenue decreased by 3.3%, while net income decreased by 6.4% compared to the same period in the previous year. Despite the unfavorable year-over-year trends, analysts should not be too concerned given the overall size of the company, and that these results may improve in the fourth quarter when a full year’s performance can be more accurately judged. Going forward, investors should keep an eye on market conditions and the company’s overall performance to make sure it remains a viable investment.
